Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody plus bevacizumab and CAPOX in RAS-mutant MSS mCRC
NCT06206096Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2021
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in colorectal cancer (metastatic) (mCRC), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective Response Rate at 3 years. Started May 2021; status: recruiting.
02
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06206096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206096.